Table 1 Baseline characteristics at beginning of follow-up: Registry-based cohort of epithelial ovarian cancers diagnosed in Norway 2004–2018
No use (N = 3627) | Aspirin only (N = 249) | Non-Aspirin NSAIDs only (N = 431) | Both (N = 18) | Total (N = 4325) | |
|---|---|---|---|---|---|
Age at diagnosis | |||||
Median (Q1, Q3) | 62.9 (54.7, 70.7) | 71.0 (65.6, 78.2) | 60.4 (53.5, 67.3) | 69.2 (63.7, 73.1) | 63.2 (55.1, 70.9) |
Health region | |||||
South-East | 2074 (57.2%) | 129 (51.8%) | 316 (73.3%) | 14 (77.8%) | 2533 (58.6%) |
West | 694 (19.1%) | 61 (24.5%) | 70 (16.2%) | 1 (5.6%) | 826 (19.1%) |
Mid | 495 (13.6%) | 31 (12.4%) | 19 (4.4%) | 2 (11.1%) | 547 (12.6%) |
North | 364 (10.0%) | 28 (11.2%) | 26 (6.0%) | 1 (5.6%) | 419 (9.7%) |
Ethnicity | |||||
Norway | 3319 (91.5%) | 239 (96.0%) | 391 (90.7%) | 17 (94.4%) | 3966 (91.7%) |
Other Nordic | 88 (2.4%) | 5 (2.0%) | 11 (2.6%) | 0 (0.0%) | 104 (2.4%) |
Rest of the world | 220 (6.1%) | 5 (2.0%) | 29 (6.7%) | 1 (5.6%) | 255 (5.9%) |
Marital status | |||||
Single | 439 (12.1%) | 19 (7.6%) | 44 (10.2%) | 0 (0.0%) | 502 (11.6%) |
Married/partnered | 2093 (57.7%) | 123 (49.4%) | 239 (55.5%) | 11 (61.1%) | 2466 (57.0%) |
Widowed/separated/divorced | 1095 (30.2%) | 107 (43.0%) | 148 (34.3%) | 7 (38.9%) | 1357 (31.4%) |
Children | |||||
0 | 554 (15.3%) | 25 (10.0%) | 59 (13.7%) | 1 (5.6%) | 639 (14.8%) |
1 | 554 (15.3%) | 33 (13.3%) | 59 (13.7%) | 1 (5.6%) | 647 (15.0%) |
2 | 1345 (37.1%) | 97 (39.0%) | 162 (37.6%) | 9 (50.0%) | 1613 (37.3%) |
3 | 807 (22.2%) | 57 (22.9%) | 111 (25.8%) | 4 (22.2%) | 979 (22.6%) |
4+ | 367 (10.1%) | 37 (14.9%) | 40 (9.3%) | 3 (16.7%) | 447 (10.3%) |
Age at first birth | |||||
Nulliparous | 554 (15.3%) | 25 (10.0%) | 59 (13.7%) | 1 (5.6%) | 639 (14.8%) |
<25 | 1763 (48.6%) | 141 (56.6%) | 215 (49.9%) | 15 (83.3%) | 2134 (49.3%) |
25–29 | 876 (24.2%) | 54 (21.7%) | 109 (25.3%) | 1 (5.6%) | 1040 (24.0%) |
30+ | 434 (12.0%) | 29 (11.6%) | 48 (11.1%) | 1 (5.6%) | 512 (11.8%) |
Education | |||||
Non/mandatory only | 973 (26.8%) | 90 (36.1%) | 131 (30.4%) | 7 (38.9%) | 1201 (27.8%) |
Secondary | 1688 (46.5%) | 125 (50.2%) | 199 (46.2%) | 10 (55.6%) | 2022 (46.8%) |
Higher | 934 (25.8%) | 32 (12.9%) | 100 (23.2%) | 1 (5.6%) | 1067 (24.7%) |
Missing | 32 (0.9%) | 2 (0.8%) | 1 (0.2%) | 0 (0.0%) | 35 (0.8%) |
Cardiovascular drugs | |||||
No | 2504 (69.0%) | 73 (29.3%) | 314 (72.9%) | 3 (16.7%) | 2894 (66.9%) |
Yes | 1123 (31.0%) | 176 (70.7%) | 117 (27.1%) | 15 (83.3%) | 1431 (33.1%) |
Statins | |||||
No | 3003 (82.8%) | 97 (39.0%) | 360 (83.5%) | 9 (50.0%) | 3469 (80.2%) |
Yes | 624 (17.2%) | 152 (61.0%) | 71 (16.5%) | 9 (50.0%) | 856 (19.8%) |
Anti-diabetics | |||||
No | 3456 (95.3%) | 219 (88.0%) | 414 (96.1%) | 16 (88.9%) | 4105 (94.9%) |
Yes | 171 (4.7%) | 30 (12.0%) | 17 (3.9%) | 2 (11.1%) | 220 (5.1%) |
SEER stage | |||||
Localized | 757 (20.9%) | 35 (14.1%) | 77 (17.9%) | 2 (11.1%) | 871 (20.1%) |
Regional | 144 (4.0%) | 17 (6.8%) | 12 (2.8%) | 0 (0.0%) | 173 (4.0%) |
Metastatic | 2613 (72.0%) | 185 (74.3%) | 326 (75.6%) | 15 (83.3%) | 3139 (72.6%) |
Missing | 113 (3.1%) | 12 (4.8%) | 16 (3.7%) | 1 (5.6%) | 142 (3.3%) |
Histology | |||||
High-grade serous | 1657 (45.7%) | 109 (43.8%) | 230 (53.4%) | 7 (38.9%) | 2003 (46.3%) |
Low-grade serous | 176 (4.9%) | 12 (4.8%) | 24 (5.6%) | 1 (5.6%) | 213 (4.9%) |
Serous unknown grade | 1116 (30.8%) | 88 (35.3%) | 102 (23.7%) | 10 (55.6%) | 1316 (30.4%) |
Endometroid | 211 (5.8%) | 9 (3.6%) | 24 (5.6%) | 0 (0.0%) | 244 (5.6%) |
Mucinous | 220 (6.1%) | 16 (6.4%) | 22 (5.1%) | 0 (0.0%) | 258 (6.0%) |
Clear cell | 185 (5.1%) | 9 (3.6%) | 24 (5.6%) | 0 (0.0%) | 218 (5.0%) |
Carcinosarcoma | 62 (1.7%) | 6 (2.4%) | 5 (1.2%) | 0 (0.0%) | 73 (1.7%) |